|
|
|
28.08.25 - 07:02
|
Innovent Reports Strong Start for Obesity Drug (Bloomberg)
|
|
|
Rachel You, CFO of Hong Kong-listed Innovent Biologics, says its obesity drug mazdutide delivered "very strong" results within two months of launch. She shares insights on "Bloomberg: The China Show" after the company's first-half earnings. (Source: Bloomberg)...
|
|
|
|
|
28.08.25 - 04:00
|
INNOVENT BIO Opens 4.3% Higher, Swings Loss into Profit of RMB830M in 1H25 (AAStocks)
|
|
|
INNOVENT BIO (01801.HK) opened 4.3% higher at $94.9 this morning (28th), with a pre-market trading volume of 533,500 shares, involving $50.6291 million.The Group's 1H25 revenue was RMB5.953 billion, up 50.6% YoY. Profit amounted to RMB834 million, representing a turnaround from a loss of RMB393 million in the same period la......
|
|
|
|
|
|
|
27.08.25 - 12:12
|
Innovent Announces 2025 Interim Results and Business Updates (PR Newswire)
|
|
|
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China, Aug. 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class......
|
|
|
27.08.25 - 12:00
|
Results: INNOVENT BIO Swings Loss into Profit of RMB834M in 1H (AAStocks)
|
|
|
INNOVENT BIO (01801.HK) has announced its interim results for the period ended June 2025.The company's revenue rose by 50.6% YoY to RMB5.953 billion. It also recorded a profit of RMB834 million, compared to a loss of RMB393 million in the same period last year. Its EPS stood at RMB0.51. No dividend was declared.~AAStocks Fin......
|
|
|
|
|
|
|
|
|
11.08.25 - 12:30
|
HKD665M Southbound Trading Net Outflow from XPENG-W (AAStocks)
|
|
|
There was HKD562.4 million and HKD187.8 million Southbound Trading net inflow to XIAOMI-W (01810.HK) and EAST BUY (01797.HK).There was HKD665 million, HKD527.9 million and HKD339.8 million Southbound Trading net outflow from XPENG-W (09868.HK), INNOVENT BIO (01801.HK) and TENCENT (00700.HK).For Southbound Trading of Shanghai-Hon......
|
|
|
07.08.25 - 12:00
|
INNOVENT BIO Expects 1H Total Product Rev. RMB5.2B+, Up 35% YoY (AAStocks)
|
|
|
INNOVENT BIO (01801.HK) announced that in 1H25, the company achieved total product revenue exceeding RMB5.2 billion, reflecting a robust growth of over 35% YoY. In 2Q25, its total product revenue was over RMB2.7 billion at YoY growth of over 30%.The continuous growth in this quarter was driven by the growth of both oncology and ......
|
|
|
|
|
30.07.25 - 12:30
|
HKD2.1B Southbound Trading Net Inflow to LI AUTO-W (AAStocks)
|
|
|
There was HKD2.1 billion, HKD872.9 million and HKD447.4 million Southbound Trading net inflow to LI AUTO-W (02015.HK), CSPC PHARMA (01093.HK) and MEITUAN-W (03690.HK).There was HKD205.3 million and HKD121.5 million Southbound Trading net outflow from SMIC (00981.HK) and INNOVENT BIO (01801.HK).For Southbound Trading of Shanghai-......
|
|
|
|
|
|
|
|
|
|
|
|
|
15.07.25 - 08:36
|
′China′s Ozempic′ pioneer inks deal with JD Health for online distribution (SCMP)
|
|
|
Innovent Biologics, the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes, will leverage JD Health's online distribution network as it seeks to grab a slice of a market that could be worth 40 billion yuan (US$5.6 billion) in a decade.
The companies will collaborate on supply chain and sales channel development ahead of Innovent's launch of mazdutide, as well as engage in a consumer education campaign.
“Innovent and JD Health will join hands to......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
